RxDoctor Payments Data

Anthony Sonn, MD

Interventional Cardiology · Saint Louis, MONPI 1265489561

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (44.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 90.1% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $48,123, more than ten times the $1,670 reported in 2019. Among interventional cardiology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$79,931in general payments, 2019–2025

Across 409 payments — averaging $195.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$72K
  • Boston Scientific$3K
  • Abbott$1K
  • Abiomed$1K
  • Medtronic$712
  • Inari Medical, Inc.$348
  • plus $2K from 24 others
$40,765in research payments, 2019–2025

Across 31 payments — averaging $1315.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$41K

What the payments were for

  • Consulting fees$13,08016%
  • Speaking & faculty fees$35,30044%
  • Travel & lodging$17,26722%
  • Food & beverage$14,21918%
  • Education$650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,931 in reported general payments places this provider in the 90th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$225,160
Medicare patients
1,126
Services billed
2,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban585$778,564
EntrestoSacubitril/Valsartan126$176,004
XareltoRivaroxaban135$165,758
Repatha SureclickEvolocumab40$45,602
Praluent PenAlirocumab19$21,412
FarxigaDapagliflozin Propanediol18$19,526
BrilintaTicagrelor29$18,253
JardianceEmpagliflozin16$17,615
Nebivolol Hcl94$6,525
Atorvastatin Calcium595$4,935
ClopidogrelClopidogrel Bisulfate469$4,864
Ranolazine ErRanolazine41$4,784
Metoprolol Succinate491$4,471
Isosorbide Mononitrate ErIsosorbide Mononitrate270$3,608
Losartan Potassium375$2,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$165$778,564585 claims
NovartisEntresto$161$176,004126 claims
Johnson & JohnsonXarelto$39$165,758135 claims
AstraZenecaFarxiga, Brilinta$135$37,77947 claims
Boehringer IngelheimJardiance$50$17,61516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →